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Abstract
Objective: Little is known of the effects of long-term GH replacement on bone mineral content (BMC)
and bone mineral density (BMD) in elderly GH-deﬁcient (GHD) adults.
Design/patients/methods: In this prospective, single-center, open-label study, the effects of 3-year GH
replacement were determined in 45 GHD patients O65 years and in 45 younger control GHD patients
with a mean age of 39.5 (S.E.M. 1.1) years. All patients had adult-onset disease and both groups were
comparable in terms of number of anterior pituitary hormonal deﬁciencies, gender, body mass index,
and waist:hip ratio.
Results: The mean maintenance dose of GH was 0.24 (0.02) mg/day in the elderly patients and 0.33
(0.02) mg/day in the younger GHD patients (P!0.01). The 3 years of GH replacement induced a
marginal effect on total body BMC and BMD, whereas femur neck and lumbar (L2–L4) spine BMC and
BMD increased in both the elderly and the younger patients. The treatment response in femur neck
BMC was less marked in the elderly patients (P!0.05 vs younger group). However, this difference
disappeared after correction for the lower dose of GH in the elderly patients using an analysis of
covariance. There were no between-group differences in responsiveness in BMC or BMD at other
skeletal locations.
Conclusions: This study shows that GH replacement increases lumbar (L2–L4) spine and femur neck
BMD and BMC in younger as well as elderly GHD patients. This supports the notion that long-term GH
replacement is also useful in elderly GHD patients.
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Introduction
GH deﬁciency (GHD) in hypopituitary adults results
in multiple abnormalities in terms of body composition,
bone mass, and glucose and lipid metabolism (1, 2, 3).
GH replacement normalizes most of these abnormalities
in adult populations including patients of various ages
(1, 2, 3). The response to GH replacement may,
however, vary in different subgroups of patients
depending on the cause and severity of disease
(1, 2, 3) as well as on whether the disease was
acquired in childhood or adulthood (4, 5).
GH secretion declines with increasing age (6, 7),
but there are distinct differences between normal elderly
subjects and elderly adults with structural hypo-
thalamic–pituitary disease. The elderly GHD adults
have lower GH secretion (8) and increased total body
fat (9) compared with age-matched healthy subjects,
whereas there is little difference in terms of lean
mass (9). The results of several studies suggest that
GH replacement in elderly GHD patients has approxi-
mately similar efﬁcacy as that in younger GHD adults in
terms of quality of life, body composition, and serum
lipid pattern (10, 11, 12, 13).
Young GHD adults have reduced bone mineral
content (BMC) and bone mineral density (BMD) (14).
Short-term (%12 months) GH replacement in relatively
young GHD adults results in unchanged or even
decreased bone mass (1, 2, 3, 14), whereas long-term
GH replacement improves BMC and BMD in open
studies (1, 2, 3, 14, 15, 16). Meta-analyses, mainly of
randomized GH treatment trials with relatively short
duration, have shown either a moderate increase in
lumbar spine BMD (17) or no change in BMD (18),
which could have been due to relatively small sample
size (18). In elderly GHD adults not receiving GH
replacement, bone mass and density are approximately
similar to that in healthy age-matched controls (13, 19,
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BMC and BMD in elderly GHD adults. In a recent review
of studies on elderly GHD adults (21), no signiﬁcant
effect of GH replacement on BMD was observed, but
previous studies have been few and of short duration
and/or included relatively few patients (21).
In this single-center, open-labeled, prospective
study, the effect of 3-year GH replacement on bone
mass and density was determined in 45 GHD patients
O65 years at the beginning of study and in 45
matched younger control GHD patients. All patients
had adult-onset GHD.
Patients and methods
Patients
Forty-ﬁve GHD adults O65 (mean age 68.7, range
65–75) years and 45 younger control GHD patients
with a mean age of 39.5 (range 27–49) years were
included in the period 1993–2006. The elderly and
the younger patients were included contemporaneously.
All patients had adult-onset disease and both groups
were comparable in terms of number of anterior
pituitary hormonal deﬁciencies, gender, body mass
index (BMI), and waist:hip ratio (Table 1). All patients
had known pituitary disease or other anterior pituitary
hormonal deﬁciencies (Table 1). Patients with a history
of Cushing’s disease or acromegaly as the cause of the
GHD were excluded since excess of cortisol or GH could
possibly affect the baseline characteristics as well as the
response to GH replacement.
Thirty-eight patients in the elderly group and 35
of the younger patients had previously undergone
pituitary surgery. Ten elderly and six younger patients
had received radiotherapy. In 44 of both the elderly
and the younger patients, the diagnosis of GHD was
based on a peak GH !3 mg/l during a stimulation test
(insulin/GHRH/glucagon). From each study group, one
patient was diagnosed based on three additional
anterior pituitary hormonal deﬁciencies and insulin-
like growth factor 1 (IGF1) SDSs !K2 S.D. of predicted
values. In addition, in these two patients, all plasma
GH concentrations were !0.33 mg/l during a 24-h
GH proﬁle with sampling every 30 min. When required,
patients in both groups received adequate and stable
therapy with glucocorticoids, thyroid hormone, gonadal
steroids, and desmopressin. However, at baseline, two
elderly women received estrogen replacement therapy,
whereas nine women received estrogen replacement
therapy in the younger group. None of the patients
received treatment with calcium, vitamin D or bispho-
sphonates during the study period.
In the elderly group, one patient died during the
study period (malignant brainstem tumor after 2.9
years) and two additional patients were excluded due
to other adverse events (colonic cancer (10 months)
and prostate cancer (3 months)). Furthermore, in the
elderly group, four patients discontinued due to lack
of compliance after 6, 12, 20, and 33 months
respectively and one patient moved to another part
of Sweden after 27 months. In the younger group,
two patients discontinued due to lack of compliance
after 10 and 15 months respectively and one patient
moved abroad after 14 months of GH replacement
therapy. All patients were, however, retained in the
statistical analysis according to the intention-to-treat
approach used.
Study protocol
This is an ongoing, prospective, open-label treatment
trial in adult GHD patients. In two patients of each
group, the initial target dose of GH was 11.9 mg/kg per
day (0.25 IU/kg per week). The dose in these patients
was gradually lowered and individualized during
the ﬁrst year of treatment. In all the remaining patients,
the dose of GH was individualized from the beginning
with the aim of normalizing IGF1 SDS (target range,
0t oC2 S.D. of predicted values) and body composition
in each patient (22).
At baseline, and then after each year of GH
replacement, physical and laboratory examinations
were performed including measurements of body
composition and bone mass. Dose titration and safety
monitoring were performed every third month during
the ﬁrst year and every sixth month thereafter. Body
weight was measured in the morning to the nearest
Table 1 Baseline characteristics of 45 elderly GHD patients and
45 younger control GHD patients. All patients had adult-onset
pituitary disease. Values are shown as the mean (S.E.M.).
Elderly Young P value
n 45 45
Men/women 34/11 34/11
Age (years) 68.7 (0.4) 39.5 (1.1) !0.001
Body height (cm) 174.0 (1.4) 175.9 (1.3) 0.31
Body weight (kg) 86.3 (2.4) 87.3 (2.1) 0.75
BMI (kg/m
2) 28.5 (0.7) 28.3 (0.7) 0.84
Waist:hip ratio 0.97 (0.01) 0.95 (0.01) 0.16
Dur. of hypopituitarism (years) 6.7 (1.1) 2.1 (0.2) !0.001
Number of additional anterior pituitary deﬁciencies
Isolated GH deﬁciency 2 3
1 Additional deﬁciency 5 5
2 Additional deﬁciencies 13 10
3 Additional deﬁciencies 25 27
Total number of additional
deﬁciencies
106 106
Cause of pituitary deﬁciency
Pituitary adenoma
a 38 32
Empty sella 2 4
Craniopharyngioma 2 3
Hypophysitis 1 2
Other causes 2 4
Dur., duration;
aPatients with previous acromegaly or Cushing’s disease
were excluded.
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measured to the nearest 0.01 m. BMI was calculated
as the weight in kilograms divided by the height in
meters squared. Waist circumference was measured in
the standing position with a ﬂexible plastic tape placed
midway between the lower rib margin and the iliac
crest, and hip girth was measured at the widest part of
the hip. No effort was made to inﬂuence the patients’
physical activity level during the study period.
Ethical considerations
Informed consent was obtained from all patients. The
study was approved by the Regional Ethics Review
Board at the University of Gothenburg and the Swedish
Medical Products Agency (Uppsala, Sweden).
Body composition, BMC, and BMD
Dual-energy X-ray absorptiometry (DXA) was used to
measure lean soft tissue (LST) and body fat, as well as
BMC and BMD in the total body, lumbar spine, and
femur neck (16, 23). From the beginning of the study
until the end of 1999, a LUNAR DPX-L scanner was
used (Scanex, Helsingborg, Sweden). Software versions
were changed several times (from 1.1 to lastly 1.35),
version 1.33 being used during the major part of this
period of the study. In-house precision error on the
scanner used, as determined from duplicate exami-
nations in ten healthy subjects, was 1.9% for total
body BMC. The relative error for LST was 1.5%. From
January 2000, a LUNAR Prodigy scanner (Scanex) was
used. Software versions were upgraded several times
during data collection, from version 5.70 to 8.10. The
precision of the scanner was estimated from repeated
measurements on different days in 30 subjects with
coefﬁcients of variation (CV) of total body BMC of
1.4%. Before the change of equipment in the end of
1999, the old and new DXA machines were cross
calibrated in 30 subjects. In both study groups, 31
patients were included before the end of 1999 and 14
patients after January 1, 2000.
Daily quality control was performed according to
manufacturer’s protocol. A spine phantom was
measured at least once a week. Every single spine
phantom measurement was compared with a baseline
value, based on a mean of ten repeated measurements.
A maximum 1.5% deviation from the baseline value
was accepted. A European phantom (COMAC-BME
Quantitative Assessment of Osteoporosis Study Group)
was measured once a year. BMD z-score, which is the
difference in S.D. of age- and sex-matched healthy
subjects, and t-score, which is the difference in S.D.o f
sex-matched young (20–39-year-old) healthy subjects,
were determined using the Lunar DPX-L software
program. The reference database used was the LUNAR
USA reference population for the region examined.
Biochemical analysis
Serum IGF1 concentration, until June 2004, was
determined by a hydrochloric acid–ethanol extrac-
tion RIA (Nichols Institute Diagnostics, San Juan
Capistrano, CA, USA). Inter-assay and intra-assay CV
were 5.4 and 6.9% respectively at a mean serum IGF1
level of 126 mg/l and 4.6 and 4.7% respectively at a
mean serum IGF1 level of 327 mg/l. From June 2004
to August 2006, serum IGF1 concentration was
determined using a chemiluminescence immunoassay
(Nichols Advantage; Nichols Institute Diagnostics)
(24). From September 2006, serum IGF1 level was
determined using an automated chemiluminescent
assay system (IMMULITE 2500, Diagnostic Products
Corp., Los Angeles, CA, USA). The individual serum
IGF1 values were compared with age- and sex-adjusted
values obtained from a reference population of 197
men and 195 women (25). The individual IGF1 SDSs
could then be calculated (26).
Statistical analysis
All the descriptive statistical results are presented as
the mean and S.E.M. Between-group differences during
the 3-year treatment period were determined using a
two-way repeated measures ANOVA of the percent
change from baseline at all time points of the study.
Within-group P values were determined using a one-
way ANOVA followed by Student–Newman–Keuls
post hoc test. Between-group P values at baseline and
at the end of study were determined using ANOVA. All
analyses were performed according to the intention-
to-treat principle (using the carry forward principle).
A two-tailed P!0.05 was considered signiﬁcant.
Results
The elderly GHD patients and the younger control GHD
patients were comparable in terms of gender, body
height, body weight, BMI, waist circumference, waist:
hip ratio, and number of anterior pituitary hormonal
deﬁciencies (Table 1). The elderly patients had, however,
longer duration of hypopituitarism compared with the
younger patients (Table 1).
GH dose and serum IGF1
The daily dose of GH was increased during the ﬁrst year
of treatment and was then slightly reduced during the
last year of GH replacement. At all time points of the
study, the dose of GH was higher in the younger patients
than in the elderly patients. Serum IGF1 levels increased
during the ﬁrst year of the study and then decreased
slightly during the last year. The elderly patients had
lower absolute level of serum IGF1 concentration than
the younger patients, but there was no between-group
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(adjustment for age and gender) was similar in both
groups at all time points and was within the normal
range (G2 S.D.) in both study groups (Table 2).
Body composition
Body height, body weight, and BMI did not change and
were not signiﬁcantly different between the two groups
(Table 2). There were sustained reductions in waist
circumference and waist:hip ratio in both groups
without any between-group difference (Table 2).
As measured using DXA, body fat was reduced and
LST was increased throughout the 3-year GH replace-
ment without any between-group difference (Table 3).
Bone mineral content
At baseline, no differences in total body and lumbar
(L2–L4) spine BMC were seen between the groups,
whereas femur neck BMC was lower in the elderly
compared with the younger GHD patients (P!0.05).
After 3 years of GH replacement, total body BMC had
increased only in the younger patients, but there was
no statistically signiﬁcant difference in responsiveness
between groups. Lumbar (L2–L4) spine BMC increased
to a similar extent in both study groups. The increase in
femur neck BMC was more marked in the younger
patients (P!0.05 vs elderly group). At the end of study,
femur neck BMC was still lower in the elderly patients
(P!0.05; Table 3).
Table 2 The dose of GH during 3-year GH replacement in 45 elderly GHD patients O65 years and 45 younger control
GHD adults and the effects of this treatment on serum IGF1 level, IGF1 SDS and anthropometric measures. All values
are shownasthe mean(S.E.M.). The statistical analysesare basedon ANOVA followedbyStudent–Newman–Keulspost
hoc test.
Baseline 1 year 2 years 3 years
P value
(0–3 years)*
Dose of GH (mg/day) Elderly 0.15 (0.01)
‡ 0.25 (0.02)
‡,a 0.26 (0.02)
†,a 0.24 (0.02)
‡,a 0.52
Young 0.24 (0.02) 0.37 (0.03)
a 0.34 (0.02)
a 0.33 (0.02)
a
Serum IGF1 (mg/l) Elderly 83 (7)
§ 170 (12)
§,a 194 (12)
§,a 187 (12)
§,a 0.57
Young 143 (11) 283 (20)
a 281 (18)
a 266 (16)
a
IGF1 SDS Elderly K1.12 (0.15) 0.69 (0.23)
a 1.24 (0.24)
a 1.12 (0.24)
a 0.15
Young K1.38 (0.23) 1.52 (0.41)
a 1.55 (0.39)
a 1.28 (0.35)
a
Body height (cm) Elderly 174.0 (1.4) 173.9 (1.4) 173.8 (1.4) 173.8 (1.4) 0.29
Young 175.9 (1.3) 176.0 (1.3) 176.0 (1.2) 175.9 (1.3)
Body weight (kg) Elderly 86.3 (2.4) 85.0 (2.3) 85.2 (2.5) 84.9 (2.4) 0.50
Young 87.3 (2.1) 86.5 (2.1) 87.4 (2.1) 86.9 (2.0)
BMI (kg/m
2) Elderly 28.5 (0.7) 28.1 (0.7) 28.2 (0.7) 28.1 (0.7) 0.81
Young 28.3 (0.7) 28.0 (0.7) 28.3 (0.7) 28.1 (0.6)
Waist circumference (cm) Elderly 100.6 (1.9) 98.3 (1.9)
a 98.2 (0.011)
a 97.9 (0.012)
a 0.30
Young 97.6 (1.7) 95.5 (1.7)
¶ 96.4 (1.7)
s 95.5 (1.7)
a
Waist:hip ratio Elderly 0.97 (0.01) 0.95 (0.01)
¶ 0.94 (0.01)
a 0.94 (0.01)
a 0.11
Young 0.95 (0.01) 0.93 (0.01)
s 0.93 (0.01) 0.92 (0.01)
a
*Between-group P values (0–3 years) are based on an analysis of the percent change or change from baseline (for the dose of GH the
percent change from the dose prescribed at the baseline visit), whereas other P values are based on an analysis of the absolute values.
†P!0.05 vs younger patients;
‡P!0.01 vs younger patients;
§P!0.001 vs younger patients;
sP!0.05 vs baseline;
¶P!0.01 vsbaseline;
aP!0.001 vs baseline.
Table 3 Effects of 3-year GH replacement in 45 GHD adults O65 years and 45 younger control GHD adults on body
composition and BMC as measured using dual-energy X-ray absorptiometry. All values are shown as the mean (S.E.M.).
The statistical analyses are based on ANOVA followed by Student–Newman–Keuls post hoc test.
Baseline 1 year 2 years 3 years
P value
(0–3 years)*
Body fat (kg) Elderly 28.6 (1.5) 26.0 (1.5)
s 25.9 (1.5)
s 25.5 (1.5)
s 0.06
Young 28.7 (1.3) 25.9 (1.4)
s 26.6 (1.4)
s 26.2 (1.3)
s
Lean soft tissue (kg) Elderly 54.2 (1.5) 55.2 (1.4)
§ 55.4 (1.5)
§ 55.5 (1.5)
§ 0.80
Young 55.3 (1.4) 56.8 (1.4)
s 56.8 (1.4)
s 56.9 (1.4)
s
Total body BMC (kg) Elderly 2.95 (0.09) 2.93 (0.09) 2.95 (0.09) 2.96 (0.09) 0.22
Young 2.99 (0.08) 3.03 (0.07) 3.09 (0.06)
§ 3.13 (0.07)
s
Lumbar (L2–L4) BMC (g) Elderly 60.7 (2.0) 61.3 (2.1) 63.2 (2.3)
s 64.2 (2.4)
s 0.97
Young 60.8 (1.7) 62.0 (1.8) 63.8 (1.8)
s 65.0 (1.8)
s
Femur neck BMC (g) Elderly 5.12 (0.16)
† 5.22 (0.15)
‡ 5.25 (0.16)
†,‡ 5.31 (0.15)
†,§ !0.05
Young 5.51 (0.11) 5.44 (0.10) 5.65 (0.12) 5.80 (0.15)
§
*Between-group P values (0–3 years) are based on an analysis of the percent change from baseline, whereas other P values are based
on an analysis of the absolute values.
†P!0.05 vs younger patients;
‡P!0.05 vs baseline;
§P!0.01 vs baseline;
sP!0.001 vs baseline.
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Total body, lumbar (L2–L4) spine, and femur neck BMD
are shown in Figs 1, 2, 3. At baseline, femur neck BMD
and t-score were lower in the elderly GHD patients
(P!0.001 vs younger GHD controls) while total body
BMD and lumbar (L2–L4) spine BMD were similar in
both groups. The elderly patients had, however, a higher
mean lumbar (L2–L4) spine z-score than the younger
patients at baseline (P!0.05). At baseline, the z-score
values were w0 (predicted based on age and gender)
in the elderly GHD group.
There was no difference between groups in the
responses to 3-year GH replacement in terms of BMD
at all skeletal sites measured. After 3 years, total body
BMD was unchanged, whereas lumbar (L2–L4) spine
BMD and femur neck BMD had increased within both
study groups. At the end of study, femur neck BMD and
t-score were still lower and lumbar (L2–L4) spinez-score
was still higher in the elderly GHD patients compared
with elderly GHD controls (P!0.001, P!0.001, and
P!0.05 respectively).
Analysis of covariance
After correction for the longer duration of hypo-
pituitarism using an analysis of covariance, the
more marked reduction in the elderly patients in
terms of femur neck BMC at baseline and the end of
study lost statistical signiﬁcance (PZ0.18 and
PZ0.06 respectively). However, the between-group
differences at baseline and the end of study in terms
of femur neck BMD and t-score remained signiﬁcant
(P!0.001).
When the higher dose of GH in the younger GHD
patients was accounted for, the between-group
difference in responsiveness in terms of femur neck
BMC lost statistical signiﬁcance (PZ0.22).
Fractures
No fractures were reported during the study period in
any study group.
Discussion
This single-center, prospective, open-label treatment
trial is, to our knowledge, the ﬁrst study that has
explored the long-term effects of GH replacement on
bone mass and density speciﬁcally in elderly GHD
adults. The 3-year GH replacement in patients O65
years with adult-onset GHD improved body composition
and increased lumbar (L2–L4) spine and femur neck
BMC and BMD.
A limitation of this study is that there was no
untreated control group. However, we compared the
effect of the 3-year GH replacement in elderly GHD
patients with that in younger GHD adults. The use of
t-scores and z-scores may also, to some extent,
compensate for the lack of an untreated control
group. Furthermore, at the end of 1999, the DXA
machine used was changed. The new DXA was,
however, calibrated to showas similar values as possible
Total body BMD
P=0.21 elderly vs young 
A
B
C
Total body t-score
P=0.60  elderly vs young 
Total body z-score
P=0.40 elderly vs young
Years
Years
g
/
c
m
2
 
(
m
e
a
n
 
±
 
S
.
E
.
M
.
)
S
.
D
.
 
(
m
e
a
n
 
±
 
S
.
E
.
M
.
)
S
.
D
.
 
(
m
e
a
n
 
±
 
S
.
E
.
M
.
)
1.10
1.14
1.18
1.22
1.26
1.30
0123
–0.6
–0.4
–0.2
0.0
0.2
0.4
0.6
–0.6
–0.4
–0.2
0.0
0.2
0.4
0.6
Young Elderly
123 0
Years
123 0
Figure 1 Total body (A) BMD, (B) t-score and (C) z-score during
3-year GH replacement in 45 GHD adults O65 years and 45
younger control GHD adults. The vertical bars indicate the S.E.M. for
the mean values shown. There were no within- or between-group
differences in terms of total body BMD, t-score, or z-score.
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z-scores, the LUNARUSA reference population was used
as the reference database throughout the study period.
Finally, a similar number of patients in both study
groups were measured using the old and the new DXA
equipments.
Two patients in each group started GH replacement
with a ﬁxed dose of GH based on body weight that was
gradually lowered and individualized. In the remaining
patients, the dose of GH was individualized from the
beginning of the study. In line with some previous
observations (13, 27), this individualized GH replace-
ment resulted in a lower dose of GH in the elderly GHD
patients than in the younger GHD patients (13, 27). The
3-year GH replacement resulted in a mean IGF1 SDS
within the normal physiological range (G2 S.D.) in both
groups. However, the mean IGF1 SDSs were in the upper
normal range (between C1 and C2 S.D. of predicted
values) after 2 years of GH replacement, and in both
groups, the dose of GH was slightly reduced during
the last year of the study. Furthermore, although the
younger patients tended to have more marked increases
in serum IGF1 concentration and IGF1 SDS than the
elderly patients, there were no statistical differences
between groups. This supports that elderly GHD
patients are sensitive to GH and that a relatively low
dose of GH can produce a signiﬁcant increase in serum
IGF1 concentration in this group of patients.
The 3-year GH replacement improved body compo-
sition in both study groups. There were sustained
reductions in waist circumference, waist:hip ratio and
total body fat without any between-group difference.
LST was increased throughout the 3-year GH replace-
ment in both groups. In line with this, several previous
studies have demonstrated that GH replacement has
approximately similar efﬁcacy in terms of improvement
of body composition in younger and elderly GHD
patients (10, 12, 13).
There was no between-group difference at baseline or
in response to the 3-year GH replacement in total body
and lumbar (L2–L4) spine BMC. The elderly patients
had lower femur neck BMC than the younger control
GHD patients at baseline and the younger patients had
more marked increase in femur neck BMC in response to
treatment. However, after correction for the longer
duration of hypopituitarism in the elderly patients using
an analysis of covariance, femur neck BMC did no
longer differ between groups. Moreover, the more
marked increase in femur neck BMC in the younger
patients lost statistical signiﬁcance when correcting for
the higher dose of GH in the younger patients. Taken
together, these ﬁndings indicate that BMC is approxi-
mately similar in elderly and younger GHD patients and
that there is no major difference in responsiveness to GH
replacement therapy.
There was no signiﬁcant difference between groups in
terms of total body BMD, t-score or z-score at baseline.
The absolute levels of femur neck BMD and t-score were
lower in the elderly patients. However, there was no
difference between groups in femur neck z-score (BMD
corrected for gender and age). This suggests that the
lower femur neck BMD in the elderly patients was
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Figure 2 Lumbar (L2–L4) spine (A) BMD, (B) t-score and (C)
z-score during 3-year GH replacement in 45 GHD adults O65 years
and 45 younger control GHD adults. The vertical bars indicate the
S.E.M. for the mean values shown. Between-group P values (0–3
years) are based on an analysis of the percent change or change
from baseline, whereas other P values are based on an analysis of
the absolute values.
aP!0.05 vs younger patients;
bP!0.05 vs
baseline;
cP!0.01 vs baseline;
dP!0.001 vs baseline.
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the lumbar (L2–L4) spine, there was no between-group
difference in BMD or t-score at baseline. However,
lumbar (L2–L4) spine z-score was higher in the elderly
compared with the younger GHD patients. This
conﬁrms that BMD, after correcting for the normal
age-related decline, is higher in elderly than in younger
GHD patients (10, 12, 13).
The responsiveness to the 3-year GH replacement, at
all skeletal sites measured, was similar in both study
groups. In both groups, total body BMD was unchanged
after 3 years, whereas lumbar (L2–L4) spine and femur
neck BMD were increased. This demonstrates that GH
replacement improves lumbar (L2–L4) spine and femur
neck BMD in younger as well as elderly GHD patients.
Furthermore, the lack of signiﬁcant effect of the 3-year
GH replacement on total body BMD in both groups is in
some accordance with the notion that GH affects bone
mass and density predominantly at weight-bearing
skeletal locations such as the lumbar spine and the
femur neck (14, 28). Therefore, the possibilitycannot be
excluded that GH indirectly increased bone mass by
improving physical activity level and muscle strength.
We did not record whether the 3-year GH replacement
increased activity level or muscle performance, but no
attempt was made to inﬂuence the patients’ physical
activity levels during the study period.
GHD adults not receiving GH replacement have
increased risk of fractures (29, 30, 31). It is not fully
clear whether GH replacement can reduce the risk of
fractures, but data based on Pﬁzer International
Metabolic Database (KIMS) (31) as well as a Swedish
multi-center study (32) may suggest a lower rate of
fractures after GH repletion. In this study, no fractures
were reported. However, the magnitudes of the
increases in lumbar (L2–L4) spine and femur neck
BMD in response to the 3-year GH replacement were
lower than those previously observed after bispho-
sphonate treatment of postmenopausal women (33).
Therefore, studies with larger study populations than
the present one are needed to explore whether GH
therapy can reduce the risk of fractures in elderly GHD
patients.
GH replacement is motivated in elderly patients with
impaired quality of life, body composition, and serum
lipid pattern (34). In several studies, GH replacement
has been shown to be similarly efﬁcient in elderly and
younger GHD adults in terms of improvement in these
variables (10, 11, 12, 13). The results of this study in
addition show approximately similar efﬁcacy of GH
replacement in terms of increased bone mass and
density. Since elderly GHD patients do not have reduced
BMD compared with age-matched healthy subjects, this
will not be an indication for GH therapy in most elderly
GHD patients. However, BMD will increase in elderly
GHD patients receiving GH replacement for other
reasons. This gives further support for the notion that
GH replacement is also useful in elderly GHD patients.
The 3-year GH replacement increased lumbar
(L2–L4) spine and femur neck BMD and BMC in elderly
GHD adults. There are, however, distinct differences
between elderly adults with GHD due to structural
hypothalamic–pituitary disease and normal elderly
subjects without severe GHD. Therefore, the extent to
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Figure 3 Femur neck (A) BMD, (B) t-score and (C) z-score during
3-year GH replacement in 45 GHD adults O65 years and 45
younger control GHD adults. The vertical bars indicate the S.E.M. for
the mean values shown. Between-group P values (0–3 years) are
based on an analysis of the percent change or change from
baseline, whereas other P values are based on an analysis of the
absolute values.
aP!0.001 vs younger patients;
bP!0.05 vs
baseline;
cP!0.01 vs baseline;
dP!0.001 vs baseline.
GH increases bone mass in elderly GHD 187 EUROPEAN JOURNAL OF ENDOCRINOLOGY (2012) 166
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bone mass in normal elderly subjects remains to be
determined.
In conclusion, this single-center, prospective, open-
label treatment trial demonstrates that 3-year GH
replacement increases lumbar (L2–L4) spine and
femur neck BMC and BMD in elderly GHD patients.
These increases were of similar magnitudes as those in
the younger control GHD adults and give further
support for the notion that GH replacement is useful
in elderly GHD patients. It remains, however, to be
investigated whether the increased BMC and BMD in
response to GH replacement will reduce the risk of
fractures in elderly GHD patients.
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